title: Effect of bed time intermediate acting insulin in NIDDM subjects refractory to a combination of sulphonylureas and biguanides.
abstract: The effect of a single dose of intermediate acting (Lente) insulin given subcutaneously at 9.00 P.M. in 22 NIDDM subjects refractory to a combination of Sulphonylureas and Biguanides was analysed. Euglycemia was achieved and maintained during the study period of three months with a mean insulin requirement of 14.22 +/- 5.98 units/day. Plasma FFA, Total cholesterol, triglyceride and VLDL-cholesterol also showed significant reduction. The level of FFA modulates hepatic glucose production, which in turn correlates positively with the fasting blood glucose. The therapeutic modality of bed time Lente Insulin based on physiological principles is an effective way of achieving glycemic control in NIDDM subjects who have become non-responsive to oral hypoglycemic agents.
authors.affiliation: Department of Diabetology, Madras Medical College.
authors.forename: V
authors.initials: V
authors.lastname: Seshiah
authors.forename: R
authors.initials: R
authors.lastname: Shanker
authors.forename: R
authors.initials: R
authors.lastname: Madhavan
authors.forename: S
authors.initials: S
authors.lastname: Venkataraman
authors.forename: A
authors.initials: A
authors.lastname: Sundaram
authors.forename: C
authors.initials: C
authors.lastname: Seshasaianam
authors.forename: J R
authors.initials: JR
authors.lastname: Sankaran
mesh_terms: D001645:Biguanides / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D002747:Chlorpropamide / Q000008:administration & dosage / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D005913:Glipizide / Q000008:administration & dosage / Q000627:therapeutic use; D005905:Glyburide / Q000008:administration & dosage / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007279:Injections, Subcutaneous; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010629:Phenformin / Q000008:administration & dosage / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D001645:Biguanides; D001786:Blood Glucose; D002747:Chlorpropamide; D004338:Drug Combinations; D005913:Glipizide; D005905:Glyburide; D006442:Glycated Hemoglobin; D049528:Insulin, Long-Acting; D008055:Lipids; D008687:Metformin; D010629:Phenformin; D013453:Sulfonylurea Compounds